Patent: 9,701,747
✉ Email this page to a colleague
Summary for Patent: 9,701,747
Title: | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
Abstract: | The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient\'s Glasgow Prognostic Score will be increased and survivability will preferably be improved. |
Inventor(s): | Smith; Jeffrey T. L. (Bellevue, WA) |
Assignee: | ALDERBIO HOLDINGS LLC (Las Vegas, NV) |
Application Number: | 14/026,467 |
Patent Claims: | see list of patent claims |
Details for Patent 9,701,747
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant | Injection | 125126 | 06/08/2006 | ⤷ Try a Trial | 2028-11-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |